Cardiologs, a cardiology diagnostics company with offices in Paris and Boston, has raised $15 million in Series A funding.
The funds are expected to go toward increasing sales and marketing throughout North America and Europe. Additional money will also be used to improve the company’s AI-powered technology platform.
Alven led the funding round, with Bpifrance, ISAI, Kurma Diagnostics, Idinvest Partners and Paris Saclay Seed Fund all also contributing investments.
“We have developed a new category of heart disease diagnostic products powered by AI that promise to revolutionize healthcare by delivering accurate, cost-effective and timely expert-level diagnostics,” Yann Fleureau, co-founder and CEO of Cardiologs, said in a prepared statement. “We are excited to work with our new partners at Alven and other earlier investors as we enter the next critical stage of our evolution as a company.”
“With its unique software built around a cutting-edge technology that blends deep learning with diagnostic clinical science and workflow, Cardiologs is already improving a traditionally manually-processed industry to generate substantial improvements in the speed, cost and accuracy of diagnostics.” François Meteyer, a partner at Alven, said in the same statement. “This will be a key differentiator to build a new AI-based category in the cardiology field, democratizing the access to instant, reliable and affordable expertise for every patient, every test, everywhere.”
Michael has more than 16 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.